Atlas Trials

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Clinical trial NCT04893486 · COMPLETED

Trial details

NCT number
NCT04893486
Sponsor
Palvella Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
BCCs in Gorlin Syndrome Patients
Start date
2021-05-06
Primary completion
2023-03-13
Enrollment
73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.